- Palabras clave > antibacterial resistance (ABR)
- Palabras clave > antibiotic resistance
- Palabras clave > antimicrobial resistance (AMR)
- Palabras clave > antimicrobial resistance surveillance
- Palabras clave > containing drug resistance - coalition-based approach
- Palabras clave > containment of antimicrobial resistance
- Palabras clave > pharmaceutical industry - performance
- Palabras clave > pharmacist - role and responsibility
- Palabras clave > research and innovation
- Palabras clave > surveillance - antibiotic resistance and antibiotic use
- Palabras clave > confinement antimicrobien
(2018; 185 pages)
The Antimicrobial Resistance Benchmark provides the first independent assessment of how pharmamaceutical companies are responding to AMR. The 30 companies in scope include those with the largest R&D divisions, the largest market presence, and specific expertise in developing critically needed medicines and vaccines. The goal of the Antimicrobial Resistance Benchmark is to guide and incentivise such companies to adopt and implement effective actions for tackling AMR. It highlights where good ideas for limiting AMR are being implemented and where action is still required. The AMR Benchmark is independently funded by UK AID and the Dutch Ministry of Health, Welfare and Sport.
Framework of analysis:
The analytical framework is structured across three Research Areas: Research & Development; Manufacturing & Production; and Appropriate Access & Stewardship. The Benchmark assesses company behaviour regarding infectious diseases and product types and in a specific geographic scope, depending on the Research Area in question. Its metrics correspond to areas where experts and stakeholders agree that pharmaceutical companies can and should be taking action to limit AMR.
What the Benchmark analyses:
The Benchmark evaluated data gathered via a detailed survey of company behaviour regarding AMR and from public sources. It included ongoing/active projects up until 8 September 2017. Data submitted by the companies or gathered from public sources was verified, cross-checked and supplemented by the Foundation’s research team using public databases, sources and supporting documentation.
The first baseline for companies:
AMR is increasingly recognised as a growing public health problem. Governments, policy-makers, farmers, doctors and pharmaceutical executives have a role to play. The Antimicrobial Resistance Benchmark provides an initial baseline measure of how pharmaceutical companies are limiting AMR. Companies and stakeholders can use this analysis to inform priorities and strategies, and learn where new incentives or stronger strategies would spur companies towards greater engagement in tackling AMR.